These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 30321704

  • 1. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
    Rattanawan C, Komanasin N, Settasatian N, Settasatian C, Kukongviriyapan U, Intharapetch P, Senthong V.
    Thromb Res; 2018 Nov; 171():171-176. PubMed ID: 30321704
    [Abstract] [Full Text] [Related]

  • 2. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
    Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J.
    J Thromb Haemost; 2007 Sep; 5(9):1862-8. PubMed ID: 17723126
    [Abstract] [Full Text] [Related]

  • 3. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 4. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
    Tàssies D, Roqué M, Monteagudo J, Martorell T, Sionis A, Arzamendi D, Heras M, Reverter JC.
    Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 6. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
    Orikaza CM, Morelli VM, Matos MF, Lourenço DM.
    Thromb Res; 2014 Jan; 133(1):120-4. PubMed ID: 24252537
    [Abstract] [Full Text] [Related]

  • 7. PAI-1 4G/5G polymorphism and plasma levels association in patients with coronary artery disease.
    Lima LM, Carvalho Md, Fonseca Neto CP, Garcia JC, Sousa MO.
    Arq Bras Cardiol; 2011 Dec; 97(6):462-389. PubMed ID: 22011808
    [Abstract] [Full Text] [Related]

  • 8. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
    Santos IR, Fernandes AP, Carvalho MG, Sousa MO, Ferreira CN, Gomes KB.
    Clin Chim Acta; 2014 Jun 10; 433():76-83. PubMed ID: 24631134
    [Abstract] [Full Text] [Related]

  • 9. Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases.
    Naderi M, Alizadeh S, Kazemi A, Tabibian S, Zaker F, Bamedi T, Kashani Khatib Z, Dorgalaleh A.
    Hematology; 2015 Mar 10; 20(2):112-8. PubMed ID: 25001244
    [Abstract] [Full Text] [Related]

  • 10. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug 10; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 11. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
    Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I, Prime Study Group.
    J Thromb Haemost; 2005 Jul 10; 3(7):1503-10. PubMed ID: 15978108
    [Abstract] [Full Text] [Related]

  • 12. The association of functional polymorphisms in genes encoding growth factors for endothelial cells and smooth muscle cells with the severity of coronary artery disease.
    Osadnik T, Strzelczyk JK, Lekston A, Reguła R, Bujak K, Fronczek M, Gawlita M, Gonera M, Wasilewski J, Szyguła-Jurkiewicz B, Gierlotka M, Gąsior M.
    BMC Cardiovasc Disord; 2016 Nov 11; 16(1):218. PubMed ID: 27835972
    [Abstract] [Full Text] [Related]

  • 13. Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes.
    Huang Q, Feng D, Pan L, Wang H, Wu Y, Zhong B, Gong J, Lin H, Fei X.
    PeerJ; 2023 Nov 11; 11():e16352. PubMed ID: 38025709
    [Abstract] [Full Text] [Related]

  • 14. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 11; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 15. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
    Hamdy M, Shaheen IA, Khallaf M, Selim YMM.
    Pediatr Blood Cancer; 2024 Jun 11; 71(6):e30959. PubMed ID: 38520679
    [Abstract] [Full Text] [Related]

  • 16. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug 11; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 17. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.
    Masini S, Ticconi C, Gravina P, Tomassini M, Pietropolli A, Forte V, Federici G, Piccione E, Bernardini S.
    Fertil Steril; 2009 Aug 11; 92(2):694-702. PubMed ID: 18774564
    [Abstract] [Full Text] [Related]

  • 18. Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
    Qian K, Xu J, Wan H, Fu F, Lu J, Lin Z, Liu Z, Liu H.
    Gene; 2015 Sep 15; 569(2):173-81. PubMed ID: 26071134
    [Abstract] [Full Text] [Related]

  • 19. Genetic and environmental influences on the fibrinolytic system: a twin study.
    Peetz D, Victor A, Adams P, Erbes H, Hafner G, Lackner KJ, Hoehler T.
    Thromb Haemost; 2004 Aug 15; 92(2):344-51. PubMed ID: 15269831
    [Abstract] [Full Text] [Related]

  • 20. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.